

Key University Research Statistics

QTR3 FYTD 2023 & 2024 - Cumulative Quarterly Comparisons

Federal Salary on Sponsored

Projects

| | Proposals | | |
|-----------------|-----------------|-----------------|----------|
| Fiscal Year | QTR3 FY2023 | QTR3 FY2024 | % Change |
| Count Submitted | 3,572 | 3,911 | 9.49% |
| Amount | \$1,264,493,483 | \$1,427,078,574 | 12.86% |
| Direct Amount | \$956,064,800 | \$1,057,426,567 | 10.60% |
| Indirect Amount | \$308,428,683 | \$369,652,007 | 19.85% |

| | Awards | | |
|-------------------------|---|---------------------------|----------|
| Fiscal Year | QTR3 FY2023 | QTR3 FY2024 | % Change |
| Count Awarded | 2,738 | 2,954 | 7.89% |
| Amount | \$694,670,585 | \$735,508,602 | 5.88% |
| Direct Amount | \$526,157,024 | \$555,859,988 | 5.65% |
| Indirect Amount | \$168,513,561 | \$179,648,614 | 6.61% |
| Federal Direct | \$305,433,700 | \$300,577,748 | -1.59% |
| Federal Indirect | \$108,787,254 | \$108,729,812 | -0.05% |
| Federal Flow-Through | \$101,807,337 | \$120,142,186 | 18.01% |
| PHS Direct | \$284,907,941 | \$260,113,362 | -8.70% |
| PHS Indirect | \$103,965,748 | \$96,281,210 | -7.39% |
| NIH Direct | \$258,744,676 | \$225,853,308 | -12.71% |
| NIH Indirect | \$100,450,995 | \$88,009,303 | -12.39% |
| Grants | \$479,258,215 | \$514,512,961 | 7.36% |
| Contracts | \$127,782,445 | \$109,684,280 | -14.16% |
| Subcontracts | \$12,920,165 | \$27,595,980 | 113.59% |
| Subgrants | \$74,684,288 | \$83,473,647 | 11.77% |
| Other | \$28,363 | \$241,735 | 752.30% |
| Trials ¹ | \$56,448,099 | \$69,770,637 | 23.60% |
| | Sponsor Type | , , . , . , | |
| Corporate | \$67,545,147 | \$82,636,115 | 22.34% |
| Federal | \$414,220,954 | \$409,307,560 | -1.19% |
| Foreign | \$10,560,577 | \$12,681,029 | 20.08% |
| Private | \$126,425,895 | \$137,359,623 | 8.65% |
| State | \$11,829,957 | \$23,932,370 | 102.30% |
| University Flow-through | \$64,088,054 | \$69,591,906 | 8.59% |
| University Flow-through | Purpose | \$09,391,900 | 6.39 /6 |
| Decemb | · · · · · · · · · · · · · · · · · · · | AF01 140 177 | 1.400/ |
| Research | \$582,792,666 | \$591,149,177 | 1.43% |
| Training | \$19,458,769 | \$13,881,904 | -28.66% |
| Other | \$92,419,150 | \$130,477,521 | 41.18% |
| | | | |
| | Award Type | | |
| Fiscal Year | QTR3 FY2023 | QTR3 FY2024 | % Change |
| New | \$274,400,258 | \$273,028,813 | -0.50% |
| | , | | |
| Count | 1,054 | 1,061 | 0.66% |
| | 4000 000 | **** | |
| Continuation | \$298,909,090 | \$332,034,604 | 11.08% |
| Count | 878 | 1,030 | 17.31% |
| Renewal | \$18,105,621 | \$29,452,653 | 62.67% |
| Kenewai | \$10,100,621 | \$49, 4 34,653 | 04.07% |
| Count | 44 | 56 | 27.27% |
| Count | | 30 | 21,21/0 |
| Supplemental | \$104,898,248 | \$98,749,901 | -5.86% |
| •• | ,, | , ., | |
| Count | 762 | 807 | 5.91% |
| Data source: EBI as of | 6/13/2024 | | |

| carrialative Q | adi cerry | companis | 70113 |
|--------------------------------------|------------------------------|------------------------------|-------------------|
| | Expenses | | |
| Fiscal Year | QTR3 FY2023 | QTR3 FY2024 | % Change |
| Direct Amount | \$490,756,258 | \$575,620,528 | 17.299 |
| Indirect Amount | \$152,728,832 | \$171,957,661 | 12.599 |
| Federal Direct | 315,582,700 | 366,845,907 | 16.249 |
| Federal Indirect | \$109,804,723 | \$121,238,186 | 10.419 |
| Federal Flow-Through | \$82,416,200 | \$98,867,925 | 19.969 |
| PHS Direct | \$293,288,375 | \$336,660,808 | 14.799 |
| | | | |
| PHS Indirect | \$105,355,499 | \$114,595,819 | 8.779 |
| Grants | \$495,970,940 | \$560,877,121 | 13.099 |
| Contracts | \$61,434,667 | \$90,883,564 | 47.949 |
| Subcontracts Subgrants | \$14,604,026 \$62,783,246 | \$18,417,405 \$71,278,757 | 26.119 13.539 |
| Other | | \$6,121,343 | |
| Clinical Trials | \$8,677,046 \$46,756,990 | | -29.459 24.519 |
| Clinical Trials | Sponsor Type | \$58,216,404 | 24.517 |
| 0 | | #c0.007.004 | 21 200 |
| Corporate | \$45,853,890 | \$60,207,334 | 31.309 |
| Federal | \$425,387,422 | \$488,084,093 | 14.749 |
| Foreign | \$6,266,344 | \$8,360,512 | 33.429 |
| Private | \$101,197,662 | \$114,387,394 | 13.039 |
| State | \$12,192,936 | \$17,432,217 | 42.979 |
| University Flow-through | \$52,333,486 | \$58,445,402 | 11.689 |
| Other Sponsor | \$253,350 | \$661,238 | 161.009 |
| | Purpose | | |
| Research | \$497,868,801 | \$582,182,037 | 16.939 |
| Training | \$27,622,810 | \$31,699,938 | 14.769 |
| Other | \$117,993,479 | \$133,696,214 | 13.319 |
| | School | | |
| School of Medicine | \$420,540,602 | \$485,588,977 | 15.47 |
| School of Public Health | \$98,890,911 | \$126,668,758 | 28.099 |
| Emory Primate Center | \$70,298,663 | \$73,696,542 | 4.839 |
| Emory College | \$27,638,249 | \$33,301,441 | 20.499 |
| School of Nursing | \$15,280,887 | \$15,993,724 | 4.669 |
| | Other | | |
| Flow-Through Expenses | \$98,589,554 | \$118,678,056 | 20.389 |
| Outgoing Sub Expenses | \$115,801,160 | \$148,096,642 | 27.899 |
| | #0 === 0 == | _ | |
| Capital Equipment Expenses | \$8,571,961 | \$10,364,016 | 20.919 |
| Square Feet of Lab Space 2 | 789,310 | 789,310 | 0.009 |
| F&A Rate (Research) | 56.00% | | |
| Industry Trial Rate | 32.00% | | |
| Fringe Rate (Fed) | 31.80% | | |
| Fringe Rate (Non-Fed) | 27.80% | 29.50% | 6.129 |
| | Personnel ³ | | |
| Individuals Paid From | | | |
| Sponsored Projects | 6,753 | 7,431 | 10.049 |
| PI's Paid From Sponsored | | | |
| Projects | 1,621 | 1,701 | 4.949 |
| Salary | on Sponsored P | rojects | |
| Figure 1 Versus | OTD0 51/0005 | OTD0 51/000 | 0/ 01 |
| Fiscal Year | QTR3 FY2023 | QTR3 FY2024 | % Change |
| Total Salary on Sponsored | \$004.064.07F | \$020 186 CC7 | 10.010 |
| Projects Federal Salary on Sponsored | \$204,964,375 | \$230,186,667 | 12.319 |

\$125,107,867

\$138,144,745

10.42%

¹ Trials based on purpose and independent of award types

² Space data not available at the time of report

³ Personnel are Award PI's & Employees Paid on Sponsored Research